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Current approaches in tissue engineering are geared toward gener-
ating tissue-specific stem cells. Given the complexity and heteroge-
neity of tissues, this approach has its limitations. An alternate
approach is to induce terminally differentiated cells to dedifferenti-
ate into multipotent proliferative cells with the capacity to re-
generate all components of a damaged tissue, a phenomenon used
by salamanders to regenerate limbs. 5-Azacytidine (AZA) is a
nucleoside analog that is used to treat preleukemic and leukemic
blood disorders. AZA is also known to induce cell plasticity. We
hypothesized that AZA-induced cell plasticity occurs via a transient
multipotent cell state and that concomitant exposure to a receptive
growth factor might result in the expansion of a plastic and
proliferative population of cells. To this end, we treated lineage-
committed cells with AZA and screened a number of different
growth factors with known activity in mesenchyme-derived tissues.
Here, we report that transient treatment with AZA in combination
with platelet-derived growth factor–AB converts primary somatic
cells into tissue-regenerative multipotent stem (iMS) cells. iMS cells
possess a distinct transcriptome, are immunosuppressive, and dem-
onstrate long-term self-renewal, serial clonogenicity, and multigerm
layer differentiation potential. Importantly, unlike mesenchymal
stem cells, iMS cells contribute directly to in vivo tissue regeneration
in a context-dependent manner and, unlike embryonic or pluripotent
stem cells, do not form teratomas. Taken together, this vector-free
method of generating iMS cells from primary terminally differenti-
ated cells has significant scope for application in tissue regeneration.
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The goal of regenerative medicine is to reconstitute damaged ordefective tissues. A supply of healthy cells capable of contributing
to tissue repair and regeneration without risk of host rejection or
malignant transformation is vital to achieving this goal. In this
regard, bone marrow transplantation and skin and bone grafts have
proven clinical utility (1–4). However, for the majority of tissues that
require regeneration, harvesting and expanding stem and progenitor
cells is a challenge, and tissue grafting is not an option due to site-
and tissue-specific limitations. Although mesenchymal stem cells
(MSCs) harvested from bone marrow or fat are regularly injected
into sites of tissue injury, there is little objective evidence that these
cells are retained at sites of injection or contribute directly to new
tissue formation (5).
Given the challenges faced in harnessing resident stem cells to
regenerate and repair tissues with low baseline turnover, research
efforts over many decades have been directed toward converting
terminally differentiated cells into stem cells. Somatic cells can
be reprogrammed into pluripotent cells by transferring their nu-
clear contents into oocytes (6), by fusion with ES cells (7, 8), or by
introducing defined transcription factors (9). However, as the di-
rect implantation of autologous pluripotent cells runs the risk of
ectopic tissue production and malignant transformation, the focus
has shifted to reprogram cells directly into specific cell types using
defined transcription factors (10). Methods to generate mouse
[e.g., neurons (11), pancreatic b cells (12), hepatocyte-like cells
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(13), cardiomyocytes (14), and hematopoietic progenitors (15, 16)]
and human [e.g., cardiomyocytes (17) and blood progenitors (4)]
cells have been reported. However, these methods require vector-
based gene transfer and are of low reprogramming efficiency.
Moreover, most tissues are a complex mix of different cell types,
and there is a need for the generation of autologous stem cells that
can directly contribute to repair and regeneration of multiple cell
types in a context-dependent manner.
Limb regeneration in salamander species is dependent not on
resident stem-cell proliferation but plasticity of differentiated cells
where mesenchymal tissues such as cartilage, muscle, and connec-
tive tissue underlying the wound epidermis lose their differentiated
characteristics and adopt a blastemal cell state (18). The blastema is
essentially a zone of mesenchymal cells that proliferate, differenti-
ate, and regenerate the limb according to the predetermined body
plan. To replicate the regenerative response in salamanders would
require the generation of plastic, proliferative cells from terminally
differentiated mammalian mesenchymal cell derivatives. During
embryonic development, cells become more specialized, and their
early transcriptional plasticity and multilineage developmental po-
tential is gradually restricted by epigenetic silencing of genes (19).
5-Azacytidine (AZA) is a nucleoside analog that is used to treat
blood disorders such as myelodysplasia and leukemia (20). AZA
demethylates DNA (21) and as an inducer of cell plasticity (22) is
used in protocols to transdifferentiate cells in vitro (23–26) and to
convert partially reprogrammed induced-pluripotent stem (iPS) cells
to fully reprogrammed iPS cells (27). However, the capacity of AZA
to induce cell plasticity has not to our knowledge been harnessed to
generate tissue-regenerative multipotent stem (iMS) cells.
We hypothesized that AZA-induced cell plasticity occurs via a
transient multi- or pluripotent cell state and that concomitent
exposure to a receptive growth factor might result in the expansion
of a plastic and proliferative population of cells. To this end, we
treated lineage-committed cells with AZA and screened a number
of different growth factors with known activity in mesenchyme-
derived tissues and report that AZA in combination with platelet-
derived growth factor–AB (PDGF-AB) converts primary somatic
cells into iMS cells. Importantly, unlike primary MSCs (5), which
may facilitate but do not directly contribute to tissue repair, iMS
cells contribute directly to in vivo tissue regeneration in a context-
dependent manner without forming teratomas.
Results
PDGF-AB/AZA-Induced Reversal of Lineage Commitment. To screen
AZA/cytokine combinations for their potential to convert lineage-
committed cells into proliferative multipotent stem cells, we first
harvested bone marrow stromal cells from mice and differentiated
them into osteocytes, chondrocytes, and adipocytes and used these
in vitro-differentiated cells as a source (SI Appendix, Fig. S1). The
quality of in vitro differentiation was assessed using immunohis-
tochemistry, immunofluorescence, and transcriptomic analyses (SI
Appendix, Fig. S2), and the cytokines [PDGFs, basic fibroblast
growth factor (bFGF), hepatocyte growth factor (HGF), insulin-
like growth factor (IGF), and vascular endothelial growth factor
(VEGF)] were chosen for their known activity on mesenchyme-
derived cells. In vitro-differentiated osteocytes, chondrocytes, and
adipocytes were cultured in media for 12 d with or without cyto-
kines. AZA was added to the cultures during the first 48 h, and a
media-only control was always used (SI Appendix, Fig. S3A).
Osteocytes, chondrocytes, and adipocytes cultured in MSC
medium supplemented with PDGF-AB and AZA demonstrated
colony-forming potential that was comparable to that of primary
bone marrow MSCs (bmMSCs) (SI Appendix, Fig. S3 B and C).
By contrast, cells treated for a similar duration with either
PDGF-AB or AZA alone or combinations of the other cytokines
with or without AZA showed limited colony-forming unit-fibro-
blast (CFU-F) potential, and these colonies could not be replated
(SI Appendix, Fig. S3 C and Insets). Notably, although primary
bmMSCs and PDGF-AB and AZA-treated osteocyte (oCFU-Fs),
chondrocyte (cCFU-Fs), and adipocyte (aCFU-Fs) cells could
be serially passaged without reprogramming factors in the
media, colonies generated from cells treated with PDGF-AB
alone plateaued and failed to replate after a few passages (SI
Appendix, Fig. S3D). Following PDGF-AB/AZA treatment, osteo-
cytes, chondrocytes, and adipocytes also adopted gene expression
profiles (SI Appendix, Fig. S4), cell surface markers (SI Appendix, Fig.
S5), and differentiation characteristics (SI Appendix, Fig. S6) of pri-
mary undifferentiated bmMSCs. These screening experiments were
repeated three times and also independently verified in a second
laboratory (SI Appendix, Fig. S7).
Conversion of Primary Osteocytes from Pdgfrα-H2B:GFP Mice into
Multipotent Proliferative MSC-Like Cells. To exclude the possibility
that PDGF-AB/AZA-induced conversion was an artifact of re-
sidual bmMSCs in our in vitro differentiation assays, we evaluated
the response of purified primary osteocytes to reprogramming [i.e.,
media + PDGF-AB/AZA (12/2 d)] or control media [i.e., media
alone (12 d), media + PDGF-AB (12 d), or media + AZA (2 d)].
To this end, we harvested and treated Lin−/CD45−/SCA1−/CD31−/
Pdgfrα-nuclear green fluorescence protein (nGFP)−/PDGFRA−/
CD51+ osteocytes (28) from long bones of Pdgfrα-H2B:GFP mice
(29) (Fig. 1A). PDGFRA is expressed on cells with MSC activity
(30), and we reasoned that conversion of osteocytes would be
accompanied by expression of nGFP in previously nGFP-negative
cells. Freshly harvested osteocytes from Pdgfrα-H2B:GFP mice
were treated with PDGF-AB/AZA for 12 and 2 d, respectively
(Fig. 1B). Primary osteocytes gained nGFP and lost CD51 ex-
pression when cultured in reprogramming media but not with
control media (Fig. 1C and SI Appendix, Fig. S8A). Untreated
osteocytes and osteocytes treated with AZA alone did not show
any CFU-F activity (SI Appendix, Fig. S8B). On the other hand,
osteocytes treated with PDGF-AB alone or PDGF-AB + AZA
showed CFU-F activity, but long-term self-renewal was limited to
osteocytes treated with both PDGF-AB and AZA (SI Appendix,
Fig. S8 B and C). To record the conversion of treated osteocytes in
real time, we also continuously live-imaged osteocytes harvested
from Pdgfrα-H2B:GFP mice after the addition of reprogramming
media (Movie S1). GFP-expressing cells were visible in reprog-
ramming media as early as day 2, and their number increased
progressively. This was accompanied by increased motility and cell
division. Three biological repeats were performed. Cell cycle anal-
ysis showed that a higher proportion of PDGF-AB/AZA-treated
osteocytes were in G2/M (SI Appendix, Fig. S8D).
The emergence of CFU-F activity was also evaluated from day
1 onwards and was noted to peak at approximately 8 d of sup-
plementation with reprogramming media (Fig. 1D). The colony-
forming potential in primary bmMSCs and treated osteocytes
(oCFU-Fs) was predominantly within the Pdgfrα-nGFP–positive
cell fraction (Fig. 1E). To interrogate qualitative differences be-
tween primary bmMSCs and reprogrammed osteocytes, micro-,
small, and large colonies generated from GFP+ stromal MSCs
and osteocyte-derived oCFU-Fs were serially passaged to evalu-
ate their growth potential (Fig. 1F). Micro colonies from primary
bmMSCs could not be serially passaged, and small colonies
waned after a few passages. Continuous culture was possible only
for the large colonies. In contrast, irrespective of size, all colonies
generated by oCFU-Fs at the first passage had the intrinsic ca-
pacity to self-renew. This suggested that within micro- and small
colonies generated from oCFU-F resided cells that had not yet
gained their full potential. To systematically evaluate this, we
performed serial replating of single cells from individual colonies
(SI Appendix, Fig. S9). Micro colonies generated by primary
bmMSCs could not be propagated, whereas cells within large
colonies retained their heterogeneous colony-forming potential
through serial passages (SI Appendix, Fig. S9, Left). In contrast,
first- and second-generation micro colonies generated by oCFU-Fs
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formed colonies that could propagate, but with serial passages, this
capacity was lost (SI Appendix, Fig. S9, Right).
To evaluate their differentiation potential, we first induced oCFU-
Fs generated from primary osteocytes into bone, cartilage, and fat
(Fig. 1G). oCFU-Fs also demonstrated in vitro differentiation po-
tential into different mesodermal [endothelium (VE-Cad, CD31,
CAV1, vWF, eNOS, ac-LDL uptake), muscle (aSMA, MYH11,
MYOCD, SRF), cardiomyocyte (NKX2.5, MEF2C, CX43, GATA4,
contractility), neuroectodermal (neural; Tuj1, GFAP, O4)] and en-
dodermal lineages (hepatocyte; Albumin, HNF-4a) with comparable
efficiency to primary bmMSCs (Fig. 1G and SI Appendix, Fig.
S10). In some respects, the potency of oCFU-Fs exceeded that
of bmMSCs. Cardiomyocytes generated from oCFU-Fs but not
bmMSCs showed spontaneous rhythmic contractility of ∼4.5 beats
per second (Movie S2), and endothelial tubes generated in matrigel
from oCFU-Fs but not bmMSCs showed PDGFRB+ pericytes
enveloping CD31+ endothelial cells (SI Appendix, Fig. S10B and
Movie S3). Neither bmMSCs nor oCFU-Fs formed teratomas when
transplanted under the kidney capsule and cannot be considered
pluripotent by this criterion. Although lacking intrinsic teratoma
potential, oCFU-Fs (ubiquitously expressing cytoplasmic GFP) when
cotransplanted with ESCs contributed to a range of mesodermal,
neuroectodermal, and endodermal lineages (SI Appendix, Fig. S11).
These data show that oCFU-Fs have intrinsic plasticity and can be
induced to differentiate into multiple tissue types in vivo in response
to regional cues (in this instance supplied by ESCs) (SI Appendix,
Fig. S11). Notably, although bmMSCs show comparable in vitro
plasticity, when cotransplanted with ESCs, they did not contribute
to cells within teratomas. These data reiterate the limited in vivo
plasticity of primary MSCs.
To evaluate the robustness of PDGF-AB/AZA in converting pri-
mary cells, we also harvested Lin−/CD45−/SCA1−/CD31−/PDGFRA−/
CD51+ osteocytes from different mouse strains. Quantitative differ-
ences were observed between mouse strains, with C57BL6 and
Q-Swiss strains showing higher oCFU-F activity (after 12 d of
treatment) than those derived from Rag1 (B6.SVJ129-Rag1tm1Bal)
mice (SI Appendix, Fig. S12), but conversion was achieved in all.
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Fig. 1. Conversion of primary osteocytes from Pdgfrα-H2B:GFPmice into renewable multipotent cells. (A) Sorting strategy for harvesting Lin−/CD45−/SCA1−/CD31−/
Pdgfrα-GFP−/CD51+ osteocytes from long bones of 8–16-wk-old mice. The Inset shows expression of RUNX2 by confocal immunofluorescence in sorted osteocytes. (B)
Schematic outline of the treatment schedule. Osteocytes from A were treated and evaluated by flow cytometry (C) and CFU-F assays (D). (C, i) Flow cytometry
profiles of freshly isolated Pdgfrα-GFP−/CD51+ osteocytes showing progressive loss of CD51 and acquisition of GFP when cultured in media containing PDGF-AB and
AZA. (ii) Primary osteocytes treated with media alone did not show acquisition of GFP. A proportion of primary MSCs harvested from bone continue to express GFP.
(D) Quantification of oCFU-F colonies (based on size) from osteocytes cultured in MSC medium supplemented for 1–12 and 1–2 d with PDGF-AB and AZA, re-
spectively. (E) CFU-F colony number (based on size) derived from sorted bmMSCs and sorted oCFU-Fs. (F) Growth curves of micro-, small, and large colonies from
bmMSCs and oCFU-Fs that were harvested at P1 and perpetuated in culture. (G) Histo- and immunohistochemistry showing multilineage differentiation potential of
converted oCFU-Fs. The histogram to the Right shows a comparison of differentiation markers (see Lower panel of images) in untreated osteocytes, bmMSCs, and
oCFU-Fs. Also see SI Appendix, Fig. S10 for an extended panel of tissue differentiation markers and quantification. bmMSCs, primary bone marrow mesenchymal
stem cells; oCFU-F, colony-forming unit–fibroblasts derived from PDGF-AB/AZA-treated osteocytes. CFU-Fs were scored as micro- (MC, 5–24 cells, <2 mM), small (SC,
≥25 cells, 2–4 mM), or large (LC, >4 mM) colonies (46). (Scale bar, 20 μm.) SD bars, SD between three independent experiments.
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Conversion of Primary Subcutaneous Adipocytes from Pdgfrα-H2B:
GFP Mice into MSC-Like Cells. To establish that PDGF-AB/AZA-
mediated conversion was not limited to primary osteocytes, we
harvested subcutaneous (s.c.) fat from Pdgfrα-H2B:GFP mice and
treated primary mature adipocytes with reprogramming or control
media and functionally analyzed the treated cells (SI Appendix, Fig.
S13A). Primary mature adipocytes (SI Appendix, Fig. S13B) were
also continuously live imaged to trace cell conversion. A proportion
of harvested mature adipocytes in reprogramming media gained
PDGFRA (nGFP) expression as early as day 2, and their number
increased during the 8-d period of live imaging (Movie S4). Pdgfra-
nGFP expression in PDGF-AB/AZA-treated adipocytes (aCFU-
Fs) at day 12 was comparable to primary adipocyte-derived MSCs
harvested from Pdgfrα-H2B:GFP mice (SI Appendix, Fig. S13C).
The colony-forming potential in primary adipocyte-derived MSCs
and in aCFU-Fs resided predominantly within the Pdgfra-nGFP–
positive cell fraction (SI Appendix, Fig. S13D), and both adipocyte-
derived MSCs and aCFU-Fs showed robust trilineage differentia-
tion potential (SI Appendix, Fig. S13E) in three biological replicates.
Conversion of Primary Human Mature Adipocytes into MSC-Like Cells.
To investigate whether primary human adipocytes were also
amenable to conversion, we harvested s.c. fat and treated ma-
ture adipocytes (SI Appendix, Fig. S14A) with reprogramming
(PDGF-AB + AZA) or control media (PDGF-AB or AZA or
media alone) substituting recombinant murine with recombinant
human PDGF-AB. By day 25, a proportion of adipoctyes treated
with reprogramming media lost their fat globules and adopted stro-
mal cell morphology (SI Appendix, Fig. S14B). Adipocytes treated
with reprogramming but not control media also demonstrated large
colony CFU-F potential, albeit lower than that of primary human
adipose-derived stromal cells (SI Appendix, Fig. S14C), long-term
growth (SI Appendix, Fig. S14D), and trilineage differentiation po-
tential (SI Appendix, Fig. S14E).
Contribution of PDGF-AB/AZA-Treated Primary Dmp1-eYFP+ Osteocytes
to in Vivo Tissue Regeneration. To evaluate contributions from treated
osteocytes to in vivo tissue regeneration, we required a trackable
marker that would be retained in cell progeny derived from osteo-
cytes. Dentin matrix acid phosphoprotein 1 (DMP1) marks termi-
nally differentiated osteocytes (31). We crossedDmp1-cre transgenic
mice with R26R-eYFP mice to generate transgenics with eYFP-
labeled osteocytes that could be treated with PDGF-AB/AZA and
traced in vivo. Consistent with their osteocytic identity, SCA1−/
CD31−/PDGFRΑ−/Dmp1eYFP+ cells coexpressed CD51 (SI Ap-
pendix, Fig. S15A) and displayed the characteristic morphology of
mature osteocytes (Fig. 2A). These cells were sorted and cultured
with or without PDGF-AB and/or AZA (Fig. 2 A and B) and eval-
uated by flow cytometry and CFU-F assays at day 12 (Fig. 2C andD)
and by in vivo transplantation assays (Fig. 2 E and F). The mor-
phology of osteocytes changed from cells with a globular soma and
fine-branching cytoplasmic extensions to flat elongated stromal cells
(Fig. 2A). In contrast to untreated cells, PDGF-AB and AZA-treated
Dmp1eYFP+ osteocytes acquired MSC markers at day 12, albeit at
A B E
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Fig. 2. PDGF-AB/AZA-treatedDmp1-eYFP osteocytes acquire MSCmarkers and CFU-F activity and show in vivomultipotency in a tissue injury model. (A) Isolation of
osteocytes from Dmp1-eYFP mice. Dmp1-eYFP+ cells also express the osteocyte marker CD51 and show morphology characteristic of osteocytes. (B) Schematic
outline of the treatment options applied to osteocytes from A. (C) Flow cytometry analysis showing the acquisition of MSC markers on primary Dmp1-eYFP+ os-
teocytes maintained in media for 12 d with (Lower) and without (Upper) PDGF-AB/AZA. (D) Number and size distribution of plastic adherent CFU-F colonies. (E)
Schematic representation of the posterior–lateral intertransverse lumber fusion model used for the implantation of Helistat collagen sponges containing PDGF-AB/
AZA-treated or control (PDGF-AB alone, AZA alone, or no PDGF-AB or AZA) Dmp1eYFP+ osteocytes. (F) Confocal images of transplanted tissues harvested at 12 wk
from a mouse engrafted with PDGF-AB/AZA-treated Dmp1eYFP cells showing the donor cell contribution to regenerating skeletal muscle, blood vessels, bone, and
cartilage. Also see SI Appendix, Fig. S15 for controls and in vivo reexpression of stroma cell markers in Dmp1-eYFP cells. (Scale bar, 20 μm.) SD bars, SD between three
independent experiments. bmMSCs, primary bone marrow mesenchymal stem cells; CS, collagen sponge; Dmp1, dentin matrix acid phosphoprotein 1; oCFU-F,
colony-forming unit–fibroblasts derived from PDGF-AB/AZA-treated osteocytes; TP, transverse process.
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varying frequency (Fig. 2C). A fraction of Dmp1eYFP+ osteocytes
(∼15%) treated with PDGF-AB/AZA acquired PDGFRA (Fig. 2C).
The PDGFRA +ve and –ve fractions were sorted and their CFU-F
activity assessed and compared with that of primary bmMSCs and
untreated osteocytes (Fig. 2D). Whereas untreated osteocytes could
not form CFU-Fs, treated osteocytes that acquired surface PDGFRA
acquired CFU-F potential. This experiment was repeated twice.
To establish whether PDGF-AB/AZA-treated osteocytes con-
tributed to tissue regeneration, cells were then loaded into Helistat
collagen sponges and transplanted into the postero-lateral gutters
adjacent to decorticated lumbar vertebrae (Fig. 2E) (32). Tissue
sections were harvested at 12 wk posttransplantation and subjected
to analysis (Fig. 2F). The surgeon (W.W.) and the scientist per-
forming the histological analysis (R.A.O.) were blinded to the
treatment groups. ReprogrammedDmp1eYFP+ oCFU-Fs expressed
MSC markers such as PDGFRA and Vimentin (SI Appendix, Fig.
S15D) and contributed to new skeletal muscle (Nestin), blood-filled
vessels (aSma), and cells of bone (BMP2) and cartilage (SOX9)
lineages (Fig. 2F). In contrast to oCFU-Fs, untreated SCA1–/CD31−/
PDGFRA−/Dmp1eYFP+ osteocytes and primary bmMSCs (derived
from b2-microglobulin-GFP mice to track their tissue contribution)
did not show evidence of in vivo proliferation or transdifferentiation.
We also evaluated the potential for PDGF-AB and AZA-
treated allogeneic bone fragments to fuse with decorticated
vertebrae in the lumbar spinal fusion mouse model used above.
Long bones were harvested from ubiquitous GFP mice (β2
microglobulin-GFP) (33), flushed to evacuate bone marrow,
fragmented, and collagenase-treated to denude surface-adherent
cells (Fig. 3A). The bone fragments were cultured in MSC me-
dium alone or supplemented with PDGF-AB and/or AZA for
12 d before transplantation (Fig. 3 B and C). Again, the surgeon
(W.W.) and the scientist performing the histological analysis
(R.A.O.) were blinded to the treatment groups. Bone fragments
treated with PDGF-AB and AZA but not untreated fragments or
fragments treated with either PDGF-AB or AZA alone showed
radiographic evidence of de novo activity both at 6 and 12 wk
(Fig. 3D). Histological sections of tissues harvested from graft
sites at 6 and 12 wk showed new woven bone with marrow-filled
spaces and cartilage adjacent to transplanted fragments (Fig. 3 E, i
and ii). Immunohistochemistry of retrieved tissues showed that
PDGF-AB + AZA-treated bone fragments but not untreated or
bone fragments treated with PDGF-AB or AZA alone showed a
rim of GFP+ cells, with some coexpressing the transient myoblast
marker α-smooth muscle actin (aSMA) and stromal cell markers
PDGFRA, CD166, and Vimentin extruding into the surrounding
matrix (SI Appendix, Fig. S16A). Cells of bone (BMP2, RUNX2),
cartilage (SOX9), skeletal muscle (Nestin, Desmin, M-Cadherin),
blood vessels (aSMA, CD146+ pericytes, and VE-Cadherin+ en-
dothelial cells), blood, and blood derivatives (Cathepsin-K osteo-
clasts) were readily identified adjacent to and were derived from
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C
Fig. 3. PDGF-AB/AZA-treated bone fragments contribute to tissue repair and regeneration. (A) A schematic representation of the experimental steps in-
volved in harvesting bone and producing fragments stripped of bone-associated stromal cells from a ubiquitous GFP (β2microglobulin-GFP) mouse.
(B) Schematic outline of the treatment options applied to bone fragments from A. (C) Schematic of the posterior–lateral intertransverse lumber fusion model
used to engraft treated and control bone fragments from B. (D) Micro-CT images of mice implanted with untreated and PDGF-AB/AZA-treated bone frag-
ments at 12 wk. Yellow arrows show allograft material, and blue arrows show de novo activity of treated bone fragments. (E, i) Hematoxylin and eosin-
stained sections of implanted fragments and surrounding tissues harvested at 6 and 12 wk. Untreated bone fragments (black dot lines) (Top) showed no new
bone generation, whereas treated bone fragments (black dot lines) (Bottom) show new woven bone (yellow dot lines) with cartilage (white dot lines) and
marrow. (ii) Graph showing graded response of PDGF-AB/AZA-treated and control bone fragments at 6 and 12 wk. (F) Confocal images of tissues surrounding
treated bone fragments showing donor cell contribution to bone, cartilage, skeletal muscle, and blood vessels. Also see SI Appendix, Fig. S16 for an extended
panel of stromal and tissue differentiation markers on donor-derived cells in vivo. (Scale bar, 20 μm.) SD bars, SD between independent experiments. *P < 0.05
and **P < 0.01 (Student’s t test). BF, bone fragment; TP, transverse process.
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transplanted PDGF-AB/AZA-treated GFP+ bone fragments at 6
and 12 wk (Fig. 3F and SI Appendix, Fig. S16B).
Given the potential clinical significance of these observations, we
specifically surveyed both 6- and 12-wk grafts from both osteocyte
and bone fragment transplants for any evidence of teratoma forma-
tion and report that there were none. There was also no difference in
G-banded mouse karyotypes following PDGF-AB/AZA treatment.
The perceived benefits of MSC transplants have been attributed to
their immunomodulatory properties. To evaluate the immunomod-
ulatory properties of oCFU-Fs, we performed mixed lymphocyte
reaction (34) assays. Both control bmMSCs and oCFU-Fs were ca-
pable of suppressing T-cell proliferation, with the latter showing more
pronounced effects (SI Appendix, Fig. S17 A, i and ii). T-cell pro-
duction of Granzyme B, an effector molecule, was also suppressed by
both bmMSCs and oCFU-Fs but not control primary osteocytes (SI
Appendix, Fig. S17B). This experiment was repeated twice.
Signaling Through PDGFRA Is Required for Cell Conversion. PDGF-
AA and PDGF-BB homodimers could not be substituted for
PDGF-AB heterodimers. Although both PDGF-AA ± AZA
and PDGF-BB ± AZA-treated osteocytes generated primary
CFU-F colonies (SI Appendix, Fig. S18 A, i and ii), the former
could only be cultured for a limited number of passages and the
latter could not be passaged at all (SI Appendix, Fig. S18B). To
dissect signaling events associated with cell conversion, we
isolated primary osteocytes from long bones and evaluated the
acquisition of CFU-F activity in the presence of inhibitors that
target various components of PDGFR signaling (Fig. 4 A–C).
Intracelullar signaling downstream of the PDGF receptor
complex is multifactorial. To guide our choice of inhibitors, we
took advantage of Ingenuity pathway analysis comparing ex-
pression levels of various mediators of PDGFR signaling between
pre– and post–PDGF-AB/AZA-treated osteocytes, which showed
activation of components of the JAK/STAT and JNK/c-JUN but
not PI3Kinase pathways in the latter (SI Appendix, Fig. S19).
pSTAT3, pJNK1, and pcJUN protein levels were significantly
elevated in osteocytes 48 h after treatment with PDGF-AB and
AZA, and these increases were modulated by their respective
inhibitors (Fig. 4D).
PDGF-AB binds PDGFR αα-receptor homodimers and
αβ-receptor heterodimers (20). Inhibition of PDGF receptor
signaling using a nonselective inhibitor, AG1296, or APA5, a
selective monoclonal PDGFRA inhibitor, abolished PDGF-
AB/AZA–mediated oCFU-F production from primary osteo-
cytes (Fig. 4 E, i and ii). Interestingly, primary osteocytes express
PDGFRB but not PDGFRA (SI Appendix, Fig. S20A). However,
within 48 h of PDGF-AB/AZA treatment, surface PDGFRA was
induced in a fraction (∼6%) of osteocytes. AZA alone or PDGF-
AB alone also induced PDGFRA expression, albeit to a lesser
extent (SI Appendix, Fig. S20B). There was a dose-dependent
decrease in oCFU-F production when osteocytes were con-
verted in the presence of JAK/STAT3 and JNK inhibitors (Fig. 4
E, iii–v). The combination of STAT3 and JNK inhibitors was
even more effective than either alone (Fig. 4 E, vi) but did not
completely abolish large colony formation at the concentrations
used. PI3kinase pathway inhibitors Wortmannin and LY294002,
on the other hand, had no impact on oCFU-F production
(Fig. 4 E, vii).
A B C D
E
Fig. 4. Signaling through PDGFRA is required for cell conversion. (A) Schematic diagram of primary osteocytes harvested by FACS from Pdgfrα-H2B:GFPmice.
(B) Schematic outline of PDGF-AB/AZA treatment of osteocytes (from A) with/without inhibitors. (C) Schematic diagram of PDGFRA signaling and choice of
targets for inhibition. (D) Western blots performed at 48 h of treatment (see B). (E) Colony-forming capacity of (i) bmMSCs, osteocytes, and PDGF-AB/AZA-
treated osteocytes with inhibitors of (ii) PDGFRA (APA5) and PDGFRA/PDGFRB (AG1296), (iii) JAK (JAK2i2 and JAKi1) and (iv) STAT3 (STAT3iVS and STAT3iP)
signaling, (v) Jnk/cJUN (JNKi1L; a Jnk inhibitor) and (vi) dual inhibition of STAT3 and JNK signaling, and (vii) PI3K (Wortmannin and LY294002) signaling.
bmMSCs, primary bone marrow mesenchymal stem cells; OC, osteocytes. SD bars, SD between independent experiments. *P < 0.05 (Student’s t test). CFU-Fs
scored as micro- (MC, 5–24 cells, <2 mM), small (SC, ≥25 cells, 2–4 mM), or large (LC, >4 mM) colonies.
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PDGF-AB/AZA-Treated Osteocytes Reexpress Pluripotency Factors and
Have a Distinct Transcriptional Profile. The global gene expression
profiles of primary osteocytes treated with PDGF-AB/AZA
place these cells closer to MSCs than to any other tissue-specific
or pluripotent stem cells (Fig. 5A). However, their profiles do
not overlap. Nucleosome occupancy and DNA methylation at
gene promoters are two early and late events, respectively, that
are associated with gene silencing that we predicted would
change during cell conversion as previously silenced genes are
reexpressed (35, 36). To this end, we used nucleosome occu-
pancy and methylome sequencing (NOMe-Seq) and allelic
bisulphite sequencing to assess nucleosome occupancy and DNA
methylation, respectively, at promoters of lineage commitment
and pluripotency genes. Runx2 expression is associated with
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Fig. 5. PDGF-AB/AZA-treated osteocytes reexpress pluripotency factors and have a distinct transcriptional profile. (A) A principal component analysis of the
transcriptomes of primary osteocytes and PDGF-AB/AZA-treated osteocytes relative to mESCs, mEpiblast stem cells, primary MSCs, and neural stem cells. (B) NOMe-
Seq analysis of Runx2 promoter accessibility in osteocytes, chondrocytes, and adipocytes is shown (Top). (Bottom) PDGF-AB/AZA-treated counterparts of osteocyte,
chondrocyte, and adipocyte. NOMe-Seq uses a DNA methyltransferase that methylates DNA at GpC sites. DNA methylation (artificially introduced by the GpC
methylase at GpC sites or endogenous methylation at CpG sites) is determined by bisulphite sequencing. GpC sites are represented as circles and are shaded black
when accessible and white when inaccessible to the DNAmethylase. Contiguous sites of DNA inaccessibility of ∼150 bp indicate sites occupied by nucleosomes (pink
bars). Sequencing results for 24 individual alleles are shown for each cell type. (C) RT-PCR expression of pluripotency genes in primary osteocytes, primary bmMSCs,
PDGF-AB/AZA-treated osteocytes, and mESCs. (D) Fraction of methylated CpGs at the promoters of Oct4, Klf4, cMyc, and Sox2 (see SI Appendix, Fig. S21 for bisulfite
sequencing results of individual alleles). (E) Confocal images of immunohistochemical stains of ESCs, bmMSCs, primary osteocytes, and PDGF-AB/AZA-treated os-
teocytes showing OCT4/Nanog, KLF4/SSEA1, cMYC/SSEA1, and SOX2/SSEA1 expression. Dual staining in PDGF-AB/AZA-treated osteocytes is shown by white arrows,
and the percentages of cells expressing single/double stains are listed. (Scale bar, 20 μm.)
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commitment to the osteogenic lineage (37) and is transcribed
from a promoter that is devoid of CpGs. Runx2 promoter alleles
were mostly free of nucleosomes in osteocytes and adipocytes
but nucleosome-dense in chondrocytes (Fig. 5B, Upper). PDGF-
AB/AZA treatment evicted nucleosomes from the Runx2 pro-
moter in all cell types (Fig. 5B, Lower).
PDGF-AB/AZA-treated osteocytes expressed pluripotency
genes Oct4, cMyc, Nanog, Klf4, Sox2, and Rex1, but their levels
were substantially lower than in ES cells (Fig. 5C). Primary os-
teocytes did not express any of these genes, whereas primary
early passage bmMSCs, although not expressing Klf4, Sox2, or
Rex1, did express cMyc at levels that were equivalent to, and Oct4
and Nanog levels that were less than, those in PDGF-AB/AZA-
treated osteocytes. Given the reexpression of pluripotency genes
in lineage-committed cells following PDGF-AB/AZA treatment,
we performed bisulphite sequencing on primary osteocytes be-
fore and after PDGF-AB/AZA treatment to assess DNA meth-
ylation profiles at the promoters of Oct4, Sox2, Klf4, and c-Myc
(Fig. 5D and SI Appendix, Fig. S21 A–D). The majority of Oct4
alleles in osteocytes showed CpG methylation at their tran-
scription start sites (TSSs). There was significant reduction of
methylation at the Oct4 TSS following PDGF-AB/AZA treat-
ment. Interestingly, almost none of the Sox2, Klf4, and c-Myc
alleles even in pretreatment osteocytes had methylation of CpGs
at their TSSs (Fig. 5D). The corresponding proteins were de-
tectable by immunohistochemistry in 1–4% of treated osteocytes
but not in pretreatment osteocytes or MSCs (Fig. 5E). It is
noteworthy that nuclear staining of these transcription factors in
treated osteocytes is sparse in contrast with the diffuse staining
seen in ESCs where these factors are abundant (Fig. 5E and SI
Appendix, Fig. S21E). There is also heterogeneity of expression
of pluripotent factors within a single converted osteocyte. The
heterogeneity and infrequency of expression of these proteins
was consistent with primary CFU-F activity (∼1% of plated cells)
observed in treated osteocytes (Fig. 1D). Taken together, these
data show that PDGF-AB/AZA treatment converts primary
lineage-committed cells into cells that have features of MSCs but
possess greater in vitro differentiation capacity and in vivo
plasticity and are distinct from pluripotent cells in their inability
to form spontaneous teratomas and low expression of pluripo-
tent factors and hence were termed iMS cells.
Discussion
iMS cells share a number of in vitro features with tissue-derived
MSCs. However, iMS cells are transcriptionally distinct and have
major in vivo advantages over MSCs, including their cellular
plasticity, retention at graft sites, and contribution to tissue
regeneration (SI Appendix, Table S1). The conversion process
requires culturing cells or tissues transiently with AZA and
PDGF-AB. AZA is administered to patients with myelodysplasia
as a daily injection for 7 consecutive days (or interrupted by the
weekend) followed by 3 wk off treatment (20). This 28-d cycle is
repeated for as long as patients show benefit and often continues
for many years. The dose of AZA (10 μM) that was required in
conjunction with PDGF-AB to generate iMS cells was selected
after testing concentrations within the peak plasma concentra-
tions measured in patients (38, 39). AZA is incorporated into
DNA and RNA (38), and PDGF-AB is both a mitogen and cell
survival factor (40–42). If PDGF-AB stimulation contributes to
the uptake of AZA and proliferation of an otherwise transient
cell population, it is unclear at this stage why PDGF-AB suc-
ceeds when the other cytokines do not. It is noteworthy that the
endogenous expression patterns of PDGF-A and PDGF-B do
not frequently overlap (40) and PDGF-AB heterodimers may be
infrequent in vivo.
It is possible that the early effect of AZA is to facilitate
reexpression of genes that are required for cell conversion. For
example, primary osteocytes lack PDGFRA expression, but as
shown in Fig. 4E, PDGFRA-mediated signaling is required for
cell conversion. Surface PDGFRA protein expression is induced
by AZA and further enhanced by PDGF-AB, which requires
PDGFRA for canonical signaling (SI Appendix, Fig. S20). Oct4
reexpression appears to be a key step in the evolution of somatic
cells toward pluripotency (43). The exact sequence of events that
leads to demethylation of the Oct4 promoter and Oct4 reex-
pression as well as nucleosome eviction at lineage-specific gene
promoters following PDGF-AB/AZA treatment will require
further investigation. Given the transcriptional connectivity of
pluripotent genes (44), Oct4 reexpression in osteocytes by pro-
moter demethylation may serve as the driver for reexpression of
the others. The erasure of epigenetic barriers at lineage-committed
genes is probably as important as the reactivation and low-level
reexpression of pluripotent genes for the plasticity of these repro-
grammed cells.
The combination of PDGF-AB and AZA is also effective in
converting primary human adipocytes in serum-free medium into
proliferative CFU-Fs that can be extensively passaged in vitro (SI
Appendix, Fig. S14). For both murine and human cells, further
research is required to establish how transplanted iMS cells ac-
tivate lineage-specific transcriptional programs in response to
local cues and the range of tissues that can be generated in vivo.
It will also be important to determine whether and for how long
undifferentiated iMS cells remain dormant at sites of trans-
plantation and retain their capacity to proliferate and differen-
tiate on demand. Although there was no evidence of systemic
spread or tumourigenicity at 12 wk, long-term evaluation will be
necessary before clinical application. Nevertheless, this efficient
vector-free method of generating autologous tissue-regenerative
cells has significant merits over current approaches.
Materials and Methods
Mice. All experiments involving mice were approved by the University of New
SouthWales animal ethics committee. The strains are detailed in SI Appendix.
BmCFU-F Isolation and ex Vivo Expansion. BmCFU-Fs were isolated from wild-
type C57BL/6, Q(S), Rag1, Pdgfrα-nGFP, or DMP1eYFP mice. Tibias and femurs
were removed, cleaned of excess soft tissues, flushed out and thoroughly
crushed using a mortar and pestle, and collagenase-treated, and the filtered
supernatant was inactivated and plated in αMEM with 20% (vol/vol) FCS and
penicillin/streptomycin/glutamine (P/S/G) (see SI Appendix).
Primary Osteocyte Isolation and Culture. Osteocytes were isolated from long
bones of 8–16-wk-old wild-type C57BL/6, Q(S), Rag1, or Pdgfrα-nGFP mice.
Cells were FACS sorted for SCA1−/CD31−/PDGFRA−/CD51+ and cultured in
DMEM + P/S/G + 100 μg/mL of ascorbate + 10% FCS (see SI Appendix).
Primary Mature s.c. Adipocyte Isolation and Culture. Primary mature s.c. adi-
pocytes were isolated from 8- to 16-wk-old PDGFRA-nGFP mice adipose tissue
using a previously described method (45). Primary adipocytes were cultured in
adipocyte medium (DMEM-HG + 10% FCS + P/S/G) at 37 °C and 5% CO2 in the
incubator for 8–10 d before exposing to reprogramming agents (see SI Appendix).
Primary Osteocyte Isolation and Culture from DMP1-eYFP Mice. Primary oste-
ocytes were isolated from long bones of 8–16-wk-old DMP1-eYFP mice. Cell
suspensions from the primary isolation procedure and resulting bone frag-
ments were cultured on type-I rat tail collagen-coated six-well plates in
αMEM + 5% FCS + P/S/G for 7 d. Outgrowths of cells from bone fragments
and cells in suspension were FACS-sorted for SCA1−/CD31−/PDGFRA−/
DMP1eYFP+ and cultured in osteocyte culture media for 3 d before re-
placement with reprogramming medium (see SI Appendix).
Cellular Reprogramming.
Reprogramming in vitro-generated mouse osteocytes, chondrocytes, and adipocytes.
In vitro-differentiated osteocytes, chondrocytes, and adipocytes were first
cultured in MSC medium (αMEM + 20% FCS + P/S/G) with or without 10 μM
AZA (Tocris Biosciences) and with or without cytokine (50 or 100 ng/mL Pdgf-
AA or Pdgf-BB or Pdgf-AB, 10 ng/mL basic fibroblast growth factor, 20 ng/mL
hepatocyte growth factor, 10 ng/mL insulin-like growth factor, and 10 ng/mL
vascular endothelial growth factor; all from R&D Systems) for 2 d and then
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cultured in MSC media with or without cytokine for 10 d. To investigate the
reprogramming cell-signaling pathways, inhibitors were added to the
reprogramming mixture from day 1 and kept for 12 d. Media was refreshed
every 3–4 d. At the end of day 12, cells were harvested for downstream analysis.
Reprogramming primary mouse osteocytes. FACS-sorted long-bone–derived SCA1−/
CD31−/PDGFRA−/DMP1eYFP+ primary osteocytes were cultured on type I rat tails
in collagen-coated 35 mm2 dishes in the osteocyte culture medium (αMEM + 5%
FCS + P/S/G) for 3 d. On day 4, osteocyte culture media was replaced with
reprogramming media (αMEM + 20% FCS + 100 ng/mL mouse recombinant
PDGF-AB + 10 μM AZA + P/S/G) and cultured for a further 48 h. At the end of
48 h, reprogramming media was replaced with αMEM + 20% FCS + 100 ng/mL
mouse recombinant PDGF-AB + P/S/Gmedia and cultured for a further 10 d with
every 3 d media change. On day 12, reprogrammed cells were harvested
for characterization.
Reprogramming primary mouse adipocytes. Harvested primary adipocytes were
cultured in adipocyte medium for 8–10 days. Reprogramming media
[αMEM + 20% (vol/vol) FCS + 100 ng/mLmouse recombinant PDGF-AB + 10 μM
AZA + P/S/G] was added on day 11 and cultured for further 48 h. At the end of
48 h, reprogramming media was replaced with αMEM + 20% FCS + 100 ng/mL
mouse recombinant PDGF-AB + P/S/G media and cultured for another 10 d
with every 3 d media change. On day 12, reprogrammed cells were harvested
for characterization.
Reprogramming primary human adipocytes. S.c. fat was harvested with consent
from patients undergoing surgery for degenerative disk disease with ap-
proval from the Prince of Wales Hospital human research ethics committee.
The s.c. adipocytes were harvested using a previously described method (45)
with modifications (see SI Appendix). Harvested primary human adipocytes
were exposed to reprogramming media containing 10 μM AZA + 200 ng/mL
human recombinant PDGF-AB + 20% autologous serum + P/S/G for 2 d and
then maintained in 200 ng/mL human recombinant PDGF-AB + 20% autol-
ogous serum + P/S/G for a further 23 d with every 3–4 d media change. On
day 25, reprogrammed adipocytes were harvested for characterization.
Inhibitor Assays. To investigate the reprogramming of cell signaling path-
ways, inhibitors were added to the reprogramming mixture from day 1 and
kept for 12 d. Media was refreshed every 3–4 d. At the end of day 12, cells
were harvested for downstream analysis (see SI Appendix).
Live Cell Imaging. Cells were imaged using an IncuCyte microscope (Essen
Bioscience) with 10× phase objective and a Nikon Ti-E microscope with a 20×
phase objective (0.45 N.A.). Images were captured every 60 and 30 min,
respectively, for 8 d (see SI Appendix).
CFU-F Long-Term Growth and Serial Clonogenicity. For details on CFU-F long-
term growth and serial clonogenicity, see SI Appendix.
In Vitro Lineage Differentiation. Reprogrammed cells were differentiated into
derivatives of all three germ layers as detailed in SI Appendix.
Teratoma Formation. Rag1mice were injected (under the kidney capsule) with
mouse HM1 ES cells (n = 2) or CFU-Fs (n = 3), osteocytes (n = 3), and oCFU-Fs
(n = 3) from β2-microglobulin-GFP mice either alone or as a mixture of
mESCs and CFU-Fs (n = 3), osteocytes (n = 3), or oCFU-Fs (n = 3) (mESCs:cells,
1:3) (see SI Appendix).
Immunohistochemistry. All antibodies and methods are listed in SI Appendix.
Gene Expression and Epigenetic Analyses. All primers are listed under SI Ap-
pendix. High-quality RNA was profiled using Illumina’s Mouse WG-6 v2.0
Bead arrays and analyzed as detailed in SI Appendix. Allelic bisulphite se-
quencing and NOMe-Seq were performed as detailed in SI Appendix. Ex-
pression data have been deposited in the Gene Expression Omnibus under
accession no. GSE59282.
Posterior–Lateral Intertransverse Lumber Fusion Model. Long bones were
harvested from either β2-microglobulin-GFP or DMP1eYFP mice; soft tissues
were removed, flushed out, fragmented, and collagenase-treated; and the
supernatant was discarded. Either bone fragments or DMP1eYFP+ osteocytes
were cultured in reprogramming or control media for 12 d and surgically
implanted into the posterior–lateral lumbar spine region (L4–L5) in Rag1
mice. At 6 and 12 wk, mice were euthanized and analyzed as detailed in
SI Appendix.
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